Cyclogest is indicated for the
1) Treatment of premenstrual syndrome, including premenstrual tension and depression.
2) Treatment of puerperal depression.

200mg daily to 400mg twice a day, by vaginal or rectal insertion. For premenstrual syndrome commence treatment on day 14 of menstrual cycle and continue treatment until onset of menstruation. If symptoms are present at ovulation commence treatment on day 12.
Use in special populations: There is no experience with use of Cyclogest in patients with impaired liver or renal function.
Paediatric population:There is no relevant use of Cyclogest in the paediatric population.
Elderly: No clinical data have been collected in patients over age 65.

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Undiagnosed vaginal bleeding. - Known or suspected progesterone sensitive malignant tumours. - Porphyria. - Severe hepatic dysfunction or disease- Known missed abortion or ectopic pregnancy. - Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

Cyclogest is not indicated in threatened miscarriage. Treatment should be discontinued in the event of a missed miscarriage.
Cyclogest should be discontinued if any of the following conditions are suspected:
myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis or retinal thrombosis.
Although risk of thromboembolism has been associated with estrogens, a link with progestins remains questionable. Therefore, in women with generally recognised risk factors for thromboembolic events, such as personal or family history, treatment with Cyclogest may further increase the risk. In these women, the benefits of Cyclogest administration need to be weighed against the risks. It should be noted however, that pregnancy itself carries an increased risk of thrombo-embolic events.
Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen.
Because progesterone may cause some degree of fluid retention, conditions that might be influenced by this factor (e.g. epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation.
A decrease in glucose tolerance has been observed in a small number of patients on estrogen- progestin combination drugs. The mechanism of this decrease is not known. For this reason, diabetic patients should be carefully observed while receiving progestin therapy.
Progesterone is metabolised in the liver and should be used with caution in patients with hepatic dysfunction.
Cyclogest contains the hormone progesterone which is present in significant concentrations in women during the second half of the menstrual cycle and during pregnancy. This should be borne in mind when treating patients with conditions that may be hormone-sensitive.
Abrupt discontinuation of progesterone dosing may cause increased anxiety, moodiness, and increased sensibility to seizures.
Use rectally if barrier methods of contraception are used.
Use rectally if patients suffer from vaginal infection (especially moniliasis) or recurrent cystitis or have recently given birth.
Use vaginally if patients suffer from colitis or faecal incontinence.

Drugs known to induce the hepatic cytochrome-P450-3A4 system (e.g. rifampicin, carbamazepine or phenytoin) may increase the elimination rate and thereby decrease the bioavailability of progesterone.
The effect of concomitant vaginal products on the exposure of progesterone from Cyclogest has not been assessed and is therefore not recommended.

Pregnancy
Cyclogest should not be used during pregnancy. There is limited and inconclusive data on the risk of congenital anomalies, including genital abnormalities in male or female infants, following intrauterine exposure during pregnancy. The rates of congenital anomalies, spontaneous abortion and ectopic pregnancies observed during the clinical trial were comparable with the event rate described in the general population although the total exposure is too low to allow conclusions to be drawn.
Lactation
Progesterone is excreted in human milk and Cyclogest should not be used during breast-feeding.

None known.

Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000), Not known (cannot be estimated from the available data)
 

SYSTEM ORGAN CLASS	Common	Uncommon	Not known
Nervous system disorder	Somnolence
Gastrointestinal disorders	Abdominal pain, Abdominal discomfort		Diarrhoea and flatulence may occur with rectal administration.
Skin and subcutaneous tissue disorders		Hypersensitivity reactions (e.g. rash, pruritus)
Reproductive system and breast disorders	Breast pain		Menstruation may occur earlier than expected, or, more rarely, menstruation may be delayed.
General disorders and administration site conditions			Soreness, some leakage of the pessary base

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard

There is a wide margin of safety with Cyclogest pessaries, but overdosage may produce euphoria or dysmenorrhoea.

Pharmacotherapeutic group: Sex hormones and modulators of the genital system; Progestogens; Pregnen-(4) derivatives. ATC code: G03DA04.
Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland.

Not applicable.

There are no preclinical data of relevance to the prescriber which are additional to those already included in other sections of the SmPC.

Also contains: vegetable fat.

None known.

Shelf-life Three years from the date of manufacture. Shelf-life after dilution/reconstitution Not applicable. Shelf-life after first opening Not applicable.

Store below 25°C in a dry place.

The product may be supplied in strip packs contained in cartons:
Carton: White backed folding box board printed on white.
Strip pack: Aluminium foil lacquer-laminated to 20μm polypropylene foil and coated on the reverse with polythene (20mg/m²). The alternative is thermoplastic film and laminated PVC to 95μm and polyethylene to 27-30μm.
Pack sizes: 5s, 12s, 15s

Not applicable.